September 15, 2016

Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine

The NYAS’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms brings together thought leaders to advance this growing frontier of patient care September 15, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:… Read More
learn more
September 15, 2016

Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine

The NYAS’ 13th Key Symposium 2016: Bioelectronic Medicine – Technology Targeting Molecular Mechanisms brings together thought leaders to advance this growing frontier of patient care September 15, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:… Read More
learn more
September 14, 2016

Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields

Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action September 14, 2016 08:00 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
September 14, 2016

Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields

Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action September 14, 2016 08:00 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
September 14, 2016

Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields

Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action Publications represent growing interest from scientific community in Novocure’s broadly applicable mechanism of action September 14, 2016 08:00 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
September 12, 2016

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Martin Romero Sanchez of Houston, Texas, is… Read More
learn more
September 12, 2016

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Martin Romero Sanchez of Houston, Texas, is… Read More
learn more
September 12, 2016

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Data demonstrate superior two, three and four year survival of patients treated with Optune™ together with temozolomide Martin Romero Sanchez of Houston, Texas, is… Read More
learn more
September 1, 2016

International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo

Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 September 01, 2016 07:00… Read More
learn more
September 1, 2016

International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo

Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 Novocure has completed enrollment of a phase 2 pilot trial in ovarian cancer and will present data on Dec. 12, 2016 September 01, 2016 07:00… Read More
learn more